Key result
Interferon-based antiviral therapy in chronic hepatitis C patients increased the rate of NT-proBNP >200 ng/L to 14.6% at week 24 compared to 2% at baseline.
Why the study?
Does interferon-based antiviral therapy increase plasma levels of NT-proBNP in patients with chronic hepatitis C?
Cohort (n=48)
Does interferon-based antiviral therapy increase plasma levels of NT-proBNP in patients with chronic hepatitis C?
Answers are grounded in this paper and cite their sources.
Interferon-based antiviral therapy in patients with chronic hepatitis C is associated with significant increases in NT-proBNP, suggesting potential therapy-induced cardiac dysfunction.
AIM: To investigate plasma levels of N-terminal pro-brain natriuretic peptide (NT-proBNP), an established marker of cardiac function, in patients with chronic hepatitis C during interferon-based antiviral therapy. METHODS: Using a sandwich immunoassay, plasma levels of NT-proBNP were determined in 48 patients with chronic hepatitis C at baseline, wk 24 and 48 during antiviral therapy and at wk 72 during follow-up. RESULTS: Plasma NT-proBNP concentrations were significantly increased (P<0.05) at wk 24, 48 and 72 compared to the baseline values. NT-proBNP concentrations at baseline and wk 24 were closely correlated (r = 0.8; P<0.001). At wk 24, 7 (14.6%) patients had NT-proBNP concentrations above 200 ng/L compared to 1 (2%) patient at baseline (P = 0.059). Six of these 7 patients had been treated with high-dose IFN-alpha induction therapy. In multiple regression analysis, NT-proBNP was not related to other clinical parameters, biochemical parameters of liver disease or virus load and response to therapy. CONCLUSION: Elevated levels of NT-proBNP during and after interferon-based antiviral therapy of chronic hepatitis C may indicate the presence of cardiac dysfunction, which may contribute to the clinical symptoms observed in patients during therapy. Plasma levels of NT-proBNP may be used as a diagnostic tool and for guiding therapy in patients during interferon-based antiviral therapy.
No takes yet. Share an insight, caveat, or question.
Jörg Bojunga (2006) conducted a cohort in chronic hepatitis C (n=48). Interferon-based antiviral therapy vs. Baseline was evaluated on NT-proBNP concentrations >200 ng/L at week 24 (p=0.059). Interferon-based antiviral therapy in chronic hepatitis C patients increased the rate of NT-proBNP >200 ng/L to 14.6% at week 24 compared to 2% at baseline.
Synapse has enriched 10 related papers. Consider them for comparative context: